Board Member
Mineralys Therapeutics, Inc. (MLYS)Equibles does not estimate personal net worth.
Get an email with a short summary when Mineralys Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get MLYS alertsJon Congleton is recorded as Board Member and CEO at Mineralys Therapeutics, Inc. (MLYS). The newest filing on record that lists Jon Congleton as Board Member and CEO at Mineralys Therapeutics, Inc. (MLYS) is dated April 8, 2026. The proxy statement of Mineralys Therapeutics, Inc. reports total compensation of $5,544,727 for Jon Congleton in fiscal 2025, including a base salary of $636,500. Disclosed compensation is on record for 4 fiscal years. Jon Congleton has spoken on 13 earnings calls and 5 other investor events across 1 company, most recently for Mineralys Therapeutics, Inc. on September 9, 2026. Mineralys Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Mineralys Therapeutics, Inc. includes Glenn P. Sblendorio (Chairman), Alexander Gold (Board Member), Alexander M. Gold, M.D. (Board Member) and 6 others.
“Look, we're very excited about the opportunity that's in front of us.”
“Welcome to our second quarter 2026 financial results and corporate update conference call. I'm joined today by Adam Levy, our chief financial officer, and Eric Warren, our chief commercial officer.”
“As we noted, the NDA for LORENDRSTAT was submitted late last year. The PDUFA date was declared in March of this year that PDUFA is with the FDA standard course.”
“We appreciate your interest and attendance. Joining me on this call is Adam Levy, our Chief Financial Officer. This meeting is being held pursuant to written notice mailed to all stockholders of record at the close of business on March 25, 2026, which is the record date determined by the Board of Directors.”
Start not stated–present
Last confirmed April 8, 2026
Start not stated–present
Last confirmed April 8, 2026
Biotechnology · Healthcare
Board Member, CEO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Mineralys Therapeutics, Inc. (MLYS) | President and Chief Executive Officer | $636,500 | $5,544,727 |
| 2024 | Mineralys Therapeutics, Inc. (MLYS) | President and Chief Executive Officer | $580,000 | $5,420,868 |
| 2023 | Mineralys Therapeutics, Inc. (MLYS) | President and Chief Executive Officer | $517,000 | $5,342,057 |
| 2022 | Mineralys Therapeutics, Inc. (MLYS) | Chief Executive Officer | $416,667 | $1,740,185 |
